HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cefonicid vs. cefoxitin for cesarean section prophylaxis.

Abstract
A randomized, prospective study compared a long-acting, second-generation cephalosporin, cefonicid (Monocid), with a short-acting, second-generation cephalosporin, cefoxitin (Mefoxin), for cesarean section prophylaxis. One hundred thirty-nine patients were enrolled, with 81 receiving a 1-g intravenous dose of cefonicid after cord clamping and 58 receiving a 2-g dose of intravenous cefoxitin after cord clamping and at 6, 12 and 18 hours postpartum. In those patients receiving cefonicid prophylaxis, endometritis incidence was 17.3% (14 of 81). This finding was not statistically significant (P less than .397) when compared to the 12.1% incidence of endometritis (7 of 58) with cefoxitin. In addition, the febrile morbidity incidence for cefonicid prophylaxis was 23.5% (19 of 81) as compared to 15.5% (9 of 58) for cefoxitin (P less than .25). Because the two drugs appear to be equally efficacious, cefonicid may be the better choice because of its markedly lower cost.
AuthorsR A Hartert Jr, G Benrubi, R J Thompson, R C Nuss
JournalThe Journal of reproductive medicine (J Reprod Med) Vol. 32 Issue 12 Pg. 907-10 (Dec 1987) ISSN: 0024-7758 [Print] United States
PMID3430499 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Cefamandole
  • Cefonicid
  • Cefoxitin
Topics
  • Adult
  • Age Factors
  • Cefamandole (analogs & derivatives, therapeutic use)
  • Cefonicid
  • Cefoxitin (therapeutic use)
  • Cesarean Section (adverse effects)
  • Endometritis (economics, prevention & control)
  • Female
  • Humans
  • Pregnancy
  • Prospective Studies
  • Random Allocation
  • Risk Factors
  • Socioeconomic Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: